Corrigendum to ‘A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours’ (European Journal of Cancer (2018) 104 (1–8), (S0959804918309705), (10.1016/j.ejca.2018.07.011))

Anas Gazzah, Valentina Boni, Jean Charles Soria, Antonio Calles, Caroline Even, Bernard Doger, Linda Mahjoubi, Rastislav Bahleda, Mahmoud Ould-Kaci, Anne Esler, Serge Nazabadioko, Emiliano Calvo

    Résultats de recherche: Contribution à un journal!!Comment/debate

    Résumé

    The authors regret that after publication, the author Emiliano Calvo would like to express the interest of disclosing all his interactions with industry, although not directly relevant to the published work, in the spirit of full transparency. His updated Declaration of Interests disclosure is below. The authors would like to apologize for any inconvenience.

    langue originaleAnglais
    Pages (de - à)198
    Nombre de pages1
    journalEuropean Journal of Cancer
    Volume119
    Les DOIs
    étatPublié - 1 sept. 2019

    Contient cette citation